How to Respond to FDA Form 483s and Warning Letters
July 10, 2017
Many medical device manufacturers receive FDA warning letters due to lack of preparation for the FDA inspection and/or an inadequate response to an FDA Form 483. The manner in which manufacturers respond to the 483 is critical in mitigating potential compliance risks and preventing the issuance of a warning letter. This article by NSF’s Kristen Grumet, published in Medical Design and Outsourcing, explains six key steps manufacturers can take when issued the FDA Form 483.
How NSF Can Help You
Get in touch to find out how we can help you and your business thrive.
What’s New with NSF
iNADO Partners with NSF to Support Members and Athletes
May 27, 2026iNADO is pleased to welcome NSF’s expertise and experience in support of its members and the athletes they serve
NSF Ends UK’s Three-Year Testing Gap with REG 31 Testing Designation
May 20, 2026NSF’s Oakdale laboratory becomes the UK’s sole facility offering comprehensive BS 6920 and REG 31 testing, closing a critical drinking water safety gap.
NSF Annual Review and Impact Report 2025 Now Live
April 20, 2026NSF has published its Annual Review and Impact Report 2025, detailing the organization’s progress over the past year and outlining strategic priorities for 2026.
Visit NSF at Making Pharma 2026
April 10, 2026Connect with our experts to discover how we help leading pharmaceutical and biotechnology companies achieve regulatory compliance and operational excellence.